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license (http://creativeof Alzheimer’s disease (AD) could be used as an enrichment tool for clinical development of
therapies. This study evaluated the prognostic performance of a genetics-based biomarker risk al-
gorithm (GBRA) established on a combination of apolipoprotein E (APOE)/translocase of outer
mitochondrial membrane 40 homolog (TOMM40) genotypes and age, then compare it to cerebro-
spinal fluid (CSF) biomarkers, neuroimaging, and neurocognitive tests using data from two inde-
pendent AD cohorts.
Methods: The GBRA was developed using data from the prospective Joseph and Kathleen Bryan,
Alzheimer’s Disease Research Center study (n 5 407; 86 conversion events [mild cognitive impair-
ment {MCI} or late-onset Alzheimer’s disease {LOAD}]). The performance of the algorithm was
tested using data from the Alzheimer’s Disease Neuroimaging Initiative study (n5 660; 457 individ-
uals categorized as MCI or LOAD).
Results: The positive predictive values and negative predictive values of the GBRA are in the
range of 70%–80%. The relatively high odds ratio (approximately 3–5) and significant net re-
classification index scores comparing the GBRA to a version based on APOE and age alone
support the value of the GBRA in risk prediction for MCI due to LOAD. Performance of the
GBRA compares favorably with CSF and imaging (functional magnetic resonance imaging)
biomarkers. In addition, the GBRA “high” and “low” AD-risk categorizations correlated well
with pathologic CSF biomarker levels, positron emission tomography amyloid burden, and neu-
rocognitive scores.
Discussion: Unlike dynamic markers (i.e., imaging, protein, or lipid markers) that may be influ-
enced by factors unrelated to disease, genomic DNA is easily collected, stable, and the technical
methods for measurement are robust, inexpensive, and widely available. The performance char-
acteristics of the GBRA support its use as a pharmacogenetic enrichment tool for LOAD delay-
of-onset clinical trials and merit further evaluation for its clinical utility in evaluating therapeutic
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It can take decades of undetected disease progression
before frank symptoms of cognitive decline are diagnosed
in Alzheimer’s disease (AD) patients. Treatments that delay
or even prevent AD dementia require robust prognostic bio-
markers of the preclinical disease process for accurate pa-
tient selection into clinical trials. Effective biomarkers
with reproducible performance characteristics that are rela-
tively inexpensive can be used for enrichment of prevention
trial cohorts and, perhaps, for subsequent identification of in-
dividuals most suitable for intervention.
To date, cerebrospinal fluid (CSF, amyloid-beta [Ab]1–
42, total tau [t-tau], and phosphorylated tau [p-tau]) and
neuroimaging biomarkers (structural/functional magnetic
resonance imaging [fMRI] and amyloid-imaging) have
been among the most studied biomarkers in individuals
with prodromal AD symptoms (mild cognitive impairment
[MCI]) or full AD dementia. These biomarker methods are
currently the “gold standard” for biomarker-based risk pre-
diction and their clinical utility is described in opinions of
the International Working Group (IWG), National Institute
of Aging-Alzheimer’s Association (NIA-AA), European
Medicines Agency (EMA), and Food and Drug Adminis-
tration (FDA) [1–4]. However, CSF biomarkers suffer
from the invasive nature of a lumbar puncture, issues
with laboratory-to-laboratory variability and reproduc-
ibility, and a lack of globally recognized reference stan-
dards and cutoff values. In addition, neuroimaging
methods require (1) specialized, expensive magnetic reso-
nance imaging (MRI) and/or positron emission tomography
(PET) scanning equipment that are only available at spe-
cific medical centers; (2) use of labile reagents; (3)
specially trained medical personnel to administer the tests
and interpret the results [5]; and (4) establishment of
threshold/cutoff values meaningful for clinical observa-
tions.
Blood-based biomarkers have the potential to be easier to
obtain and more economical; platforms to test these are
widely available at medical facilities around the world. Un-
fortunately, there are multiple factors that can confound the
measurement of RNA, protein, and/or metabolite levels in
the blood and correlation with AD disease state, including
diseases comorbid with AD, various medical treatments,
and even diet. Strong prognostic biomarkers that can predict
future onset of AD would ideally be dichotomous (marker
positive/negative) and not continuously variable, i.e., where
different analyte levels correspond to different risks and
assignment of arbitrary cutoff values are imposed.A simple, genetics-based biomarker risk algorithm
(GBRA) using a combination of apolipoprotein E (APOE,
ε2,ε3,ε4), translocase of outer mitochondrial membrane 40
homolog (TOMM40) rs10524523 variable length poly-T
repeat polymorphism (TOMM400523) genotypes, and age
has been developed as a prognostic tool for assessing AD
age-of-onset (AOO) in asymptomatic people [6]. In this
study, we present data on the predictive characteristics of
the GBRA to identify people at risk for MCI due to AD
[7], and comparative data for CSF and neuroimaging
(fMRI) based biomarkers, and neurocognitive testing. The
overall hypothesis to be tested is that the combination of
age, APOE genotype, and TOMM400523 genotype, used in
an algorithm based on historical MCI/AD AOO data, will
outperform algorithms based on age alone or APOE geno-
type in predicting conversion from normal cognition to de-
mentia (phenoconversion) when assessed by receiver
operating curves (ROC) analysis or other well-defined statis-
tical methods to compare biomarkers. Also compared are the
categories for risk of phenoconversion with widely used bio-
markers for AD including CSF-based biomarkers, Pittsburgh
Compound B (PIB)-PET imaging of amyloid burden, and
neurocognitive tests.2. Methods
2.1. AD cohorts
The Joseph and Kathleen Bryan, Alzheimer’s Disease
Research Center (Bryan-ADRC) Memory, Health and Ag-
ing Study (MHA) cohort measured age of AD onset of
subjects followed at the Bryan-ADRC at Duke University
[8]. MHA participants included MCI patients from the
Duke Memory Disorders Clinic and individuals who
were enrolled in the Bryan-ADRC autopsy program as
controls; some of these individuals have been followed
for 10–20 years. The latter individuals were cognitively
normal when they enrolled and many have progressed to
AD or MCI. Study subjects were followed annually with
the National Alzheimer’s Coordinating Center-Unified
Data Set (NACC-UDS) protocol and battery [9] of neuro-
psychological tests to monitor cognitive changes and diag-
nose onset of cognitive impairment and probable AD
dementia. Importantly, the subjects were followed pro-
spectively to capture the earliest clinical symptoms of
the disease process and were all assessed using validated
tests including the NACC-UDS, along with standardized
practices and definitions of symptom onset and cognitive
status at one research center, the Bryan-ADRC. Cases of
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gist for individuals considered to be clinically in the pro-
dromal stage of AD [10]. Details on the identification of
prodromal AD in population settings are described in
Mayeux et al. [11]. These criteria are the basis of the
criteria for MCI due to AD used for the development of
the GBRA and for the TOMORROW clinical trial
[6,12]. Some of the cases were eventually autopsied to
confirm the AD diagnosis.
For this analysis, the Alzheimer’s Disease Neuroimaging
Initiative (ADNI, ClinicalTrials.gov identifier, NCT00106899)
cohort refers to data from the ADNI-1 study conducted at
multiple sites within North America with retrospective
assessment of imaging (MRI and PET) and biomarkers
from cognitively normal controls, MCI subjects defined by
the ADNI protocol included subjects with MMSE scores
.23, isolated memory impairment based on education
adjusted memory scores on the Wechsler Memory Scale
Logical Memory III scale used by ADNI and a clinical de-
mentia rating (CDR) [13] global score of 0.5. Study partici-
pants with AD were diagnosed using standard criteria
(NINCDS/ADRDA criteria for probable AD) [14] and
were of mild severity at enrollment, with MMSE scores be-
tween 20 and 26 and CDR scores between 0.5 and 1.0. For
evaluation of the performance of the GBRA to predict con-
version from normal cognition to MCI and/or AD, data from
healthy controls (HCs) who converted to MCI or AD were
used to identify AOO. Furthermore, for AD participants,
the best estimate of year of onset of symptoms (collected
at screening) was used. Data for this cohort were obtained
from the ADNI database (adni.loni.usc.edu). Data were
downloaded on January 28, 2014 and included TOMM40
rs10524523 (TOMM40.csv), APOE (APOERES.csv), CSF
biomarkers (UPENNBIOMK*.csv), PET imaging (PIBPET-
SUVR.csv), and neuropsychological tests (CDR.csv,
MMSE.csv). The entire ADNI-1 cohort (n 5 660) that had
complete records for APOE, TOMM400523, and neurocog-
nitive tests (MMSE and CDR) was used for the primary anal-
ysis; 332 subjects had CSF biomarker data and 66 had PET
data available. The ADNI was launched in 2003 as a public-
private partnership, led by principal investigator Michael W.
Weiner. The primary goal of ADNI has been to test whether
serial MRI, PET, other biological markers and clinical and
neuropsychological assessment can be combined to measure
the progression of MCI and early AD. For up-to-date infor-
mation, see www.adni.info.org.
Clinical data from only Caucasian subjects of both the
Bryan-ADRC and ADNI cohorts were used in this investiga-
tion.2.2. Development of the GBRA
The GBRAwas previously developed to enrich a clinical
trial with subjects at an elevated near-term risk for onset of
cognitive decline to evaluate efficacy of a therapeutic; de-
tails of the development of the GRBA are provided in thestudy by Crenshaw et al. [6]. In brief, the algorithm incorpo-
rates an individual’s current age along with TOMM400523
and APOE genotypes (Fig. 1). This figure summarizes the
risk stratification scheme that implements the GBRA. The
low-risk stratum includes carriers of APOE ε2/ε2 and
APOE ε2/ε3 and a proportion of APOE ε3/ε3 subjects.
TOMM400523 long (L)/L (i.e., APOE ε4/ε4 in white Cauca-
sians) subjects and those with very long (VL)/L, which cor-
responds to an earlier APOE ε3/ε4 AOO distribution, are
classified as high risk. There are three common genotypes
with risks that change as a function of age, where the high
risk versus low risk distinction is determined by location
of the age where the fraction of the cohort without cognitive
impairment starts to decline rapidly from a level of approx-
imately 80%. Individuals with the TOMM400523 short (S)/L
genotype, one of the two APOE ε3/ε4 groups, become high
risk at age 75 years; 523 S/S subjects (a subgroup of the
APOE ε3/ε3 subjects) enter the high-risk category at age
78; and 523 S/VL (a subgroup of the APOE ε3/ε3 subjects)
become high risk at age 77. TOMM400523 S/S–APOE ε2/ε4
subjects are included in the high-risk stratum as a conse-
quence of carriage of an APOE ε4–L haplotype (note that
,3% of Caucasians possess this genotype). TOMM400523
VL/VL subjects that correspond to the oldest APOE ε3/ε3
AOO distribution are classified as low risk.
Fig. 2 illustrates the relationships further using
Kaplan-Meier (KM) curves showing the clear relationship
between the APOE and TOMM400523 genotypes in Cau-
casians that is based in the linkage disequilibrium be-
tween the variants and specifically how TOMM400523
increases the precision of AOO estimation for the
Bryan-ADRC cohort. In Caucasians, the APOE ε4 allele
is almost always (.98% of the time) linked to a
TOMM400523 “L” allele. Therefore, in this case, the
two alleles are interchangeable for genotype/phenotype
association (e.g., the APOE ε4/ε4 and TOMM400523
L/L curves would be identical and TOMM400523 does
not contribute additional information to AOO.) APOE ε3
and APOE ε2 are linked to TOMM400523 S or VL
alleles and contribute information to the APOE ε3/ε4
and ε3/ε3 AOO curves as shown. APOE ε2 allele linkage
to TOMM400523 alleles occurs in equivalent ratios to
APOE ε3 alleles and, therefore, the differentiation of
the different AOO curves shown in Fig. 2 is not a
consequence of APOE ε2 carriage in opposition to
APOE ε3 but instead a consequence of the different
TOMM400523 alleles. As shown in Fig. 2, the major
changes in slope of most of the KM curves for late-
onset Alzheimer’s disease (LOAD) AOO occur between
ages 67 and 83 years. After age 83, the risk for develop-
ment of cognitive impairment is high for people of all ge-
notypes except those carrying APOE ε2/ε2 or APOE ε2/
ε3. The strong age by TOMM400523 interaction and infor-
mativeness of the combination of APOE and
TOMM400523 genotypes observed in Fig. 2 is the basis
for the GBRA.
Fig. 1. GBRAAD-risk algorithm. Flowchart and Tables show the process for the generation of the risk assessment for MCI due to AD using the GBRA. Risk of
high or low is assigned based on APOE genotype, TOMM400523 genotype, and current age. Abbreviations: GBRA, genetics-based biomarker risk algorithm;
AD, Alzheimer’s disease; APOE, apolipoprotein E; TOMM40, translocase of outer mitochondrial membrane 40 homolog; MCI, mild cognitive impairment.
M.W. Lutz et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 30-44 332.3. APOE and TOMM500523 genotyping
Samples were genotyped for APOE and TOMM400523 at
Polymorphic DNA Technologies (Polymorphicdna.com,
Alameda, CA, USA). The APOE genotype was defined by
the rs429358 and rs7412 SNPs. The homopolymer poly-T
rs10524523 was genotyped as described elsewhere [6,15].
Alleles of the rs10524523 variable length poly-T repeat
polymorphism variant (TOMM400523) were classified as
described in the literature [6], according to the length of
the poly-T repeats: S (,21T), L (21–29T), and VL
(.29T). For quality control purposes, each sample was gen-
otyped twice. The consensus calls of the TOMM400523 ge-
notypes based on the replicate assays were used for the
genetic analysis.2.4. Statistical analysis
Assessment of the performance of the GBRA is chal-
lenging due to the heterogeneity of the clinical diagnoses
of LOAD and MCI [16]. As noted for each analysis of algo-
rithm performance, clinical diagnoses of an event included
either MCI or LOAD. Standard measures of predictive per-
formance (sensitivity, specificity, positive predictive value
[PPV], and negative predictive value [NPV]) are reported
in addition to the odds ratio for the occurrence of a specified
event(s) within a 5-year interval. Likelihood ratios are re-
ported, weighted by prevalence for positive prediction
(1) and negative prediction (2). Ninety-five percent confi-
dence intervals (CIs) are reported for each performance
measure.
Fig. 2. Age at onset of cognitive impairment as a function of TOMM400523 genotype in the Bryan-ADRC cohort. The curves represent the fit of a Kaplan-Meier
survival analysis model to the data. The red line corresponds to APOE ε4/ε4; the two green lines correspond to APOE ε3/ε4, and the three blue lines correspond
to APOE ε3/ε3. Adapted from Crenshaw et al. [6]. Abbreviations: TOMM40, translocase of outer mitochondrial membrane 40 homolog; APOE, apolipoprotein
E; VL, very long; S, short; L, long; Bryan-ADRC, Joseph and Kathleen Bryan, Alzheimer’s Disease Research Center.
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mance characteristics of alternate risk models composed of
different measures, e.g., genetics, biochemical markers and
clinical data (e.g., age) and different parameter settings
(e.g. age thresholds) for the GBRA. Receiver operating
curves (ROC) are provided which compare the GBRA to
forms of the risk model based on age alone, APOE genotype
alone, and the combination of age and APOE ε4 carrier sta-
tus (carriage of at least one APOE ε4 allele). Logistic regres-
sion modeling and step-wise logistic regression modeling
were performed to compare alternate forms of the risk
model: reporting P values for each term, r2 values, area un-
der the curve (AUC), and Bayesian information criterion. To
assess the sensitivity of the GBRA to changes in the age
thresholds, all age-dependent thresholds (as shown in
Fig. 1) were increased or decreased by 2 and 4 years and
the resulting sensitivity and specificity were plotted. To pro-
vide a statistical measure of improvement of the GBRAwith
the TOMM400523 genotype in comparison with a model
based on APOE genotype and age alone, the net reclassifica-
tion index (NRI) was calculated for both cohorts [17] and is
reported with the corresponding P value. The index quan-
tifies accurate changes in categories based on events (subject
develops MCI or AD) or nonevents (subjects remain cogni-
tively normal) comparing the two versions of the risk algo-
rithm. Statistically significant improvement is observed if
subjects move to the correct classification with the full
version of the model and the NRI is compared with a null hy-
pothesis of no improvement. Measures of sensitivity and
specificity for CSF related and imaging biomarkers from
multiple studies as reported in the qualification opinionsby the European Medicines Agency (EMA) [2,4] are used
for comparison with the GBRA.
For analysis of risk assessment by the GBRA in com-
parison with neurocognitive scores, CSF biomarkers and
PET amyloid burden and APOE, TOMM400523 genotype,
and age at diagnostic assessment were used to classify risk
for MCI due to AD as low or high based on the GBRA.
For biomarkers that are expressed on an interval scale
(CSF biomarkers (Ab1–42 and p-tau), PET imaging mea-
sures of Ab load (standardized uptake value ratio,
SUVR), and MMSE), a t test was performed to compare
the mean levels of each biomarker between the two risk
groups. P values ,.05 were considered significant. A
Tukey-Kramer honestly significant difference test was
done to account for multiple comparisons when
comparing the six TOMM400523 genotypes with PET im-
aging markers of Ab load.
All statistical analyses were performed using SAS
(version 9.3; SAS Institute, Cary NC, USA) or JMP Geno-
mics (version 6.0; SAS Institute).3. Results
The Bryan-ADRC cohort was used to develop the
GBRA; the ADNI cohort was used to assess the perfor-
mance of the GBRA in an independent data set. Presented
here are preliminary data on the predictive value of a
GBRA based on age and two genetic variants: APOE ge-
notype and TOMM400523 genotype. The performance
characteristics for the GBRA are compared with the per-
formance characteristics of a CSF biomarker based on
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PPV of 65% (53–77%, 95% CI) in a recent meta-
analysis [2]. These CSF markers were recently qualified
by the EMA for selecting patients for clinical trials of
AD therapeutics [2].
3.1. Cohort characteristics
Table 1 summarizes the characteristics of the discovery
(Bryan-ADRC) and replication (ADNI) cohorts. For each
of the three diagnostic criteria (healthy controls (HCs),
MCI, and AD), the demographics, global measures of cogni-
tive function, and disease severity (MMSE and CDR score)
are reported. The mean age of subjects (78–79 years) diag-
nosed with MCI and AD did not differ between the cohorts
or between the diagnostic groups. The ages of the cogni-
tively normal subjects in the Bryan-ADRC cohort (mean
age of 72 years) were significantly different (P , .0001)
from the ADNI cohort (mean age of 76 years). The fre-
quency of APOE ε4 carriage did not differ significantly
(P 5 .11, Fisher’s exact test) between the two cohorts. The
MMSE scores for the AD diagnostic category for the
Bryan-ADRC cohort were significantly lower than those
for the ADNI cohort (P , .0001). There was a higher prev-
alence of MCI and AD in the ADNI cohort (69%) compared
with that in the Bryan-ADRC cohort (40%).Table 1
Bryan-ADRC and ADNI cohort characteristics
Characteristics
ADNI
No. at baseline (No. at 5 y)
Age, mean (SD), y
Male: female ratio
APOE ε4 allele carrier, %
Mini-mental state examination score, mean (SD) (MMSE)
Cognitive dementia rating scale global score (n) (CDR)
Cognitive dementia rating scale sum of boxes (CDR-SB), mean (SD)
Cerebrospinal fluid Ab1–42 level at baseline, mean (SD) pg/mL, n
Cerebrospinal fluid p-tau level at baseline, mean (SD) pg/mL, n
PET index of amyloid burden at 1 y, (standardized uptake value ratio, SUVR)
Bryan-ADRC
n
Age, mean (SD), y
Male: female ratio
APOE ε4 allele carrier, %
Mini-mental state examination score, mean (SD) (MMSE)
Cognitive dementia rating scale global score (n) (CDR)




CDR global score, P value
CDR sum of boxes, P value
Abbreviations: SD, standard deviation; AD, Alzheimer’s disease; MCI, mild cog
Disease Research Center; ADNI, Alzheimer’s Disease Neuroimaging Initiative.
NOTE. For comparison of age between diagnostic categories, *P , .05, **P ,
ference in age between the MCI and AD categories for either cohort.3.2. Performance of the GBRA
Table 2 summarizes the performance characteristics of
the GBRA for prediction of risk of MCI or AD in the two co-
horts. The performance of the GBRA for prediction of AD
risk was similar within the two patient cohorts for sensitivity
(0.60 vs. 0.65; Bryan-ADRC vs. ADNI) but showed greater
specificity for the Bryan-ADRC patients (0.81) than the
ADNI patients (0.61). For the Bryan-ADRC cohort, a
reasonable balance between PPV and NPV is obtained at
68% and 76%, respectively. For the ADNI cohort, PPV is
relatively high at 79%, whereas NPVis calculated to be 44%.3.3. Comparison of alternate forms of the GBRA
Fig. 3 shows the sensitivity and specificity of the GBRA
in comparison with structural forms that include only age,
APOE genotype, and APOE genotype and age. The full
version of the algorithm includes age, APOE genotype,
and TOMM400523 genotype and offers an appropriate bal-
ance between sensitivity and specificity in comparison
with forms of the algorithm that do not include
TOMM400523 genotype, notably to gain specificity at the
expense of some sensitivity. For the ADNI cohort, the high-
est sensitivity is obtained using subset models that contain






205 (203) 304 (178) 151 (279)
76 (5) 78 (5)* 78 (5)
108:97 202:102 80:71
26.3 52.6 64.9
29.1 (1.0) 27.0 (1.8) 23.5 (2.1)
0 0.5 0.5 (82) 1.0 (69)
0.03 (0.12) 1.61 (0.90) 4.14 (1.63)
204 (32) 102 162 (55) 153 146 (45) 77
25.4 (15.1) 101 36.2 (18.8) 153 39.7 (17.8) 77
1.49 (0.32) 18 1.77 (0.41) 26 1.94 (0.36) 22
242 79 86
72 (9) 79 (9)** 78 (8)**
115:191 38:58 42:64
34.3 43.8 56.7
29.2 (1.1) 27.7 (2.3) 22.1 (6.8)
0 (220) 0.5 (21) 0 (21) 0.5 (57) 1 (1) 0 (2) 0.5 (35) 1.0 (27)
2 (6) 3 (14)





nitive impairment; Bryan-ADRC, Joseph and Kathleen Bryan, Alzheimer’s
.001. Comparisons are to the healthy controls. There was no significant dif-
Table 2
Performance characteristics of the biomarker algorithm
Statistic Bryan-ADRC study ADNI study
PPV 68 (60–74) 79 (74–83)
NPV 76 (71–80) 44 (38–50)
Prevalence 0.40 (0.36–0.44) 0.69 (0.66–0.73)
Sensitivity 0.60 (0.53–0.67) 0.65 (0.61–0.70)
Specificity 0.81 (0.76–0.85) 0.61 (0.53–0.67)
OR 4.9 (3.4–7.3) 2.9 (2.1–4.1)
NRI Z score (with APOE and age) 1.7 3.8
NRI P .09 .0001
NRI events reclassified up
(true positives)
0.07 0.04
NRI events reclassified down
(false positives)
0.25 0.25
NRI nonevents reclassified up
(false negatives)
0.05 0.01
NRI nonevents reclassified down
(true negatives)
0.32 0.42
LR (1) 2.10 (1.66–2.66) 3.74 (3.06–4.57)
LR (2) 0.32 (0.27–0.39) 1.28 (1.15–1.44)
Abbreviations: PPV, positive predictive value; NPV, negative predictive
value; OR, odds ratio for development of MCI or LOAD; MCI, mild
cognitive impairment; LOAD, late-onset Alzheimer’s disease; NRI, net
reclassification improvement (Z score); APOE, apolipoprotein E; Bryan-
ADRC, Joseph and Kathleen Bryan, Alzheimer’s Disease Research
Center; ADNI, Alzheimer’s Disease Neuroimaging Initiative; LR, likeli-
hood ratio, weighted by prevalence for positive prediction (1) and nega-
tive prediction (2).
NOTE. Values are shown with 95% confidence limits. NRI reclassifica-
tion numbers are given as the proportion of events reclassified (events clas-
sified up are improved prediction, nonevents reclassified down are improved
prediction).
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the subset of models based on APOE genotype alone; how-
ever, this increased specificity comes at the expense of
reduced sensitivity. The performance of the algorithm differs
between the two cohorts in terms of specific values of sensi-
tivity and specificity; however, the same relative comparison
of sensitivity and specificity is observed for the comparison
of the subset models to the full GBRA.
The specific age thresholds that are used in the GBRA
correspond to the location on each TOMM400523 KM curve
where the fraction of the Bryan-ADRC cohort without
cognitive impairment starts to decline rapidly from a level
of approximately 80%. Including these age-dependent
thresholds has a statistically significant effect on the perfor-
mance of the GBRA as assessed by changes in AUC.
Inclusion of the thresholds improves AUC for both the
Bryan-ADRC cohort (P 5 .005), which is expected because
these data were used to develop the algorithm, and for the
ADNI cohort (P 5 .04), supporting the specific thresholds
in a replication data set.
Fig. 4A and B and Table 3 provide analytical data on the
sensitivity and specificity of several models for prediction of
conversion from cognitively normal to dementia (MCI or
AD) in a 5-year time period. Statistical comparisons of the
models are for contrasts of the AUC. The simplest model in-
cludes only age. Two models include terms for each geno-type (APOE and 0523) individually plus age. The most
complex model includes age and the two genotypes. The
GBRA is implemented as shown in Fig. 1. For the GBRA,
sensitivity can be improved at the expense of specificity by
lowering the age threshold (Fig. 5) and for the ROC analysis,
age is varied to show the trade-off between sensitivity and
specificity. For the Bryan-ADRC cohort (Fig. 4A), there is
a notable, modest but not statistically significant improve-
ment of the full model containing age, APOE genotype,
and TOMM400523 genotype in comparison with age or
age combined with either of the two genotypes. For the
ADNI cohort (Fig. 4B), the two genotypes either individu-
ally or together plus age give relatively the same ROC curves
that are substantially better than age alone (P , .0001). For
both cohorts, the combination of APOE and age in compar-
ison with the combination of age and TOMM400523 pro-
vides slightly better performance, although not statistically
different. Area under the curve (AUC) values for the
ADNI cohort are consistently lower than AUC values for
the Bryan-ADRDC cohort. The AUC for the GBRA is not
statistically different from the combination of APOE and
age for either cohort.
An alternate statistical framework to test for improve-
ment of the GBRAwith the TOMM400523 genotype in com-
parison with a model based on APOE genotype and age
alone, the NRI was calculated for both cohorts [17]. The
NRI was highly significant (P5 .0001) for the ADNI cohort
but was not significant (P5 .09) for the Bryan-ADRC cohort
(Table 2). A recent critical review of NRIs for evaluation of
risk prediction has identified several advantages and disad-
vantages (notably, taking an unweighted average of the re-
classification categories to produce the index) of the
method [18]. After the recommendation of this review, we
have reported all reclassification categories in Table 2 and
have supplemented the NRI analysis with a full description
of the operating characteristics of the alternate risk models
in Table 3 and Fig. 4.3.4. Age sensitivity of the GBRA
The sensitivity and specificity of the GBRA depends, in
part, on the age thresholds that are set in the algorithm. These
thresholds were set based on the KM analysis of the Bryan-
ADRC cohort with respect to development of MCI or AD by
identifying the age where the slope of the KM curve changes
most rapidly, starting at approximately 20% affected (sub-
jects with MCI or AD). The age thresholds that are used in
the algorithm provided optimal stratification of low- and
high-risk subjects for the cohort. However, changing the
age threshold affects both sensitivity and selectivity. Fig. 5
shows the trade-off in sensitivity and selectivity for the
GBRA predictions for both the Bryan-ADRC and ADNI co-
horts when the GBRA age thresholds are increased or
decreased in intervals of 2 or 4 years. This analysis also
shows the sensitivity of the algorithm to changes in the
age thresholds.
Fig. 3. Comparison of the performance of the full GBRA (age, APOE genotype, and TOMM400523 genotype) with versions of the risk algorithm based on age
alone, age and APOE ε4 carrier status, or APOE genotype and age. Abbreviations: GBRA, genetics-based biomarker risk algorithm; APOE, apolipoprotein E;
Bryan-ADRC, Joseph and Kathleen Bryan, Alzheimer’s Disease Research Center; ADNI, Alzheimer’s Disease Neuroimaging Initiative.
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biomarkers
The sensitivity and specificity of the GBRA compares
favorablywithCSFand imaging (fMRI)biomarkersmeasured
in the ADNI cohort and recently qualified for clinical trials
research by the EMA as shown in Fig. 6. Although there are
reports of several biomarkers based on Ab1–42 and t-tau that
show improved sensitivity and specificity in comparison
with the GBRA, there is considerable variability in the mea-
surement of these biomarkers across clinical centers, based
on multiple literature reports as shown in Fig. 6 [2,19–26].3.6. Correlation of risk assessment by the GBRA with
neurocognitive scores, CSF biomarkers, and PET amyloid
burden3.6.1. Neurocognitive scores
For the Bryan-ADRC cohort, subjects predicted to be low
risk by the GBRA showed a significantly (P, .0001) higher
mean MMSE score (28.37 6 0.24) in comparison with sub-
jects predicted to be high risk (26.10 6 0.29; Table 4). This
pattern was also observed in the ADNI cohort with high-risk
subjects having a significantly (P, .0001) lower mean score
(26.45 6 0.13) compared with the mean score for low-risk
subjects (27.37 6 0.16). For reference, the difference inmean MMSE scores for HC and MCI subjects in the
ADNI cohort is 2.1, whereas the difference between HC and
AD subjects is 5.6. The difference in mean MMSE scores
for HCs and MCI subjects in the Bryan-ADRC cohort is
1.5, whereas the difference between HC and AD subjects
is 7.1. Highly statistically significant (P, .0001) differences
in CDR global and CDR sum of boxes scores are observed
between the high- and low-risk groups for both the Bryan-
ADRC and the ADNI cohorts (Table 4). These results
demonstrate that the GBRA correctly stratifies subjects by
neurocognitive performance.
3.6.2. CSF biomarkers (Ab1–42 and p-tau)
For the ADNI cohort, subjects predicted to be high risk
by the GBRA showed a significantly (P , .0001) lower
mean level of CSF Ab1–42 (157.15 6 3.78) in comparison
with subjects predicted to be low risk (195.59 6 4.67;
Table 4). For reference, the difference in mean Ab1–42
levels for HC and MCI subjects is 42, whereas the differ-
ence between HC and AD subjects is 58. Subjects predicted
to be high risk by the GBRA showed a significantly
(P , .0001) higher mean level of p-tau (36.70 6 1.28) in
comparison with subjects predicted to be low risk
(29.17 6 1.58). The difference in mean p-tau for HC and
MCI subjects is 10.8, whereas the difference between HC
and AD subjects is 14.3. These results show that the
GBRA risk categories of high and low are associated with
Fig. 4. Comparative receiver operating curves for statistical models based on age, APOE genotype, and TOMM400523 genotype. (A) Bryan-ADRC cohort and
(B) ADNI cohort. Abbreviations: Bryan-ADRC, Joseph and Kathleen Bryan, Alzheimer’s Disease Research Center; ADNI, Alzheimer’s Disease Neuroimaging
Initiative; APOE, apolipoprotein E.
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ally observed in HC and MCI or AD patients (e.g., lower
CSF Ab1–42 and higher p-tau).
3.6.3. PET imaging measures of Ab load
Amarked difference is observed in PET imagingmeasures
of Ab load (standardized uptake value ratio, SUVR) between
high- and low-risk subjects for the ADNI cohort (Table 4).
Subjects predicted to be high risk by the GBRA showed a
significantly (P, .0001) higher (worse) standardized uptake
value ratio (SUVR) measurement of amyloid burden (mean
SUVR 1.906 0.06, n5 40) in comparison with subjects pre-
dicted to be low risk (mean SUVR 1.526 0.07, n5 30). For
reference, mean SUVR for HC subjects is 1.496 0.08, mean
SUVR for MCI subjects is 1.766 0.08, and mean SUVR for
AD subjects is 1.91 6 0.08. The difference in mean SUVR
for HC and MCI subjects is 0.27, whereas the difference be-
tween HC and AD subjects is 0.42.4. Discussion
We evaluated a classification of risk as high or low, based
on the likelihood of phenoconversion to MCI or ADwithin a
5-year time frame, typical for a delay-of-onset clinical trial,
based on age, APOE genotype, and TOMM400523 geno-
type. A retrospective analysis of the GBRA in two cohorts
with a relatively high prevalence of phenoconversion from
normal cognition to MCI or AD (40% Bryan-ADRC cohort,
69% ADNI cohort) is a suitable study to determine the
correlation between risk categories determined by the
GBRA and blood-, CSF-, and imaging-based biomarkers.
For both cohorts, there was a strong correlation between
the risk categories determined by the GBRA and neurocog-
nitive measures (MMSE and CDR). For the ADNI cohort,
where extensive data were available for CSF (Ab1–42 and
p-tau) and imaging biomarkers, a similar strong correlation
between risk categories and these biomarkers of
Table 3
Logistic regression modeling of age, APOE genotype, and TOMM400523
genotype for 5-year conversion from cognitively normal to MCI or
Alzheimer’s disease
Model terms AUC (SE) Term P value r2 BIC
Bryan-ADRC
Age 0.65 (0.03) .0001 0.04 510
APOE genotype 0.68 (0.03) .0001 0.07 501.5
523 genotype 0.65 (0.03) .0001 0.04 510.9
Age 1 APOE 0.81 (0.03) 0.14 472.5
Age 1 0523 0.79 (0.02) 0.1 486.6
Age 1 APOE10523 0.82 (0.02) 0.14 472.5
Best model 0.82 (0.02) 0.14 472.5
ADNI
Age 0.56 (0.02) .02 0.01 821.1
APOE genotype 0.69 (0.02) .0001 0.09 762.2
523 genotype 0.67 (0.02) .0001 0.06 775.7
Age 1 APOE 0.72 (0.02) 0.1 756.8
Age 1 0523 0.70 (0.02) 0.08 770.4
Age 1 APOE10523 0.72 (0.02) 0.1 756.8
Best Model 0.72 (0.02) 0.1 756.8
Abbreviations: APOE, apolipoprotein E; AUC, area under the curve; SE,
standard error; MCI, mild cognitive impairment; Bryan-ADRC, Joseph and
Kathleen Bryan, Alzheimer’s Disease Research Center; BIC, Bayesian in-
formation criterion; ADNI, Alzheimer’s Disease Neuroimaging Initiative;
TOMM40, translocase of outer mitochondrial membrane 40 homolog.
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and magnitude of the correlation was consistent with previ-
ous publications which compared the biomarker to diagno-
ses of MCI, AD, or HC [27].
The performance of the GBRA for prediction of AD risk
was similar within the two patient cohorts for sensitivityFig. 5. Age sensitivity of GBRA illustrates the relationship between sensitivity an
age-dependent thresholds were increased or decreased by 2 and 4 years and the
genetics-based biomarker risk algorithm; Bryan-ADRC, Joseph and Kathleen Bryan
imaging Initiative.(0.60 vs. 0.65; Bryan-ADRC vs. ADNI) but showed greater
specificity for the Bryan-ADRC patients (0.81) than the
ADNI patients (0.61). These findings reflect the different
disease prevalence in the two collections resulting from ap-
proaches used to create the cohorts (Bryan-ADRC cogni-
tively normal subjects followed prospectively, ADNI
normal, MCI, and AD subjects at time of entry). The diag-
nostic standards are also different for the two cohorts: the
Bryan-ADRC cohort is single site with a clinical diagnosis;
ADNI is multi-site; and AOO was either estimated at
screening for AD patients or obtained from cognitively
normal individuals who converted to MCI/AD during the
study; follow-up intervals are also different. Prevalence in
specific populations is an important consideration for utili-
zation of the biomarker. Measures such as PPV, NPV, odds
ratio, and NRIs vary accordingly with the unique properties
of the cohort, including prevalence. Measures including
sensitivity, specificity, and AUC correspond only to the
ability of the biomarker or algorithm to correctly identify
individuals who will convert from normal cognition to
MCI/AD. We have included the former measures to assess
more fully their performance in cohorts that have similarity
to planned clinical trials for prevention of AD. Individuals
recruited for clinical trials from memory clinics will likely
have considerably higher prevalence for MCI than the gen-
eral public.
ROC and comparative analysis of AUC showed that the
combinations of APOE genotype, TOMM400523 genotype,
and age outperformed age in sensitivity and specificity
for prediction of phenoconversion. For the Bryan-ADRCd specificity with age. Baseline corresponds to the algorithm as defined. All
resulting sensitivity and specificity were plotted. Abbreviations: GBRA,
, Alzheimer’s Disease Research Center; ADNI, Alzheimer’s Disease Neuro-
Fig. 6. Comparative performance of the GBRA, CSF (combination of amyloid b and tau), and fMRI biomarkers. Abbreviations: GBRA, genetics-
based biomarker risk algorithm; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; HC, healthy control; fMRI, functional magnetic reso-
nance imaging.
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performed age and either genotype (APOE or TOMM40) in
terms of sensitivity and specificity. For the replication
ADNI cohort, the performance of age combined with
either or both genotypes was equivalent. For both cohorts,
the combination of age and APOE genotype provided
slightly better performance than age and TOMM400523
genotype, although the difference was not statistically sig-
nificant. It was surprising that the AUC for the GBRA did
not show a statistically significant improvement for the
ADNI cohort when compared with the combination of
APOE genotype and age considering the statistical signif-
icance of the age interaction terms. Testing in additional
replication cohorts from longitudinal observational
studies with more precise estimation of AOO of MCI/
AD will be needed to more clearly define the performance
of the GBRA.
The relationship between the genetic (APOE and
TOMM400523) and age components of the GBRA and
overall sensitivity and specificity is consistent for bothTable 4




High 157.15 6 3.78 36.70 6 1.28




High 0.45 6 0.02 0.52 6
Low 0.31 6 0.02 0.17 6
Abbreviations: GBRA, genetics-based biomarker risk algorithm; CSF, cerebro
mini-mental state examination; Ab1–42, amyloid-beta; p-tau, phosphorylated tau; C
SUVR. standardized uptake value ratio.
NOTE. *P , .001; **P , .0001.the Bryan-ADRC and ADNI cohorts; improved test perfor-
mance is observed for slightly younger versus older ages.
This age sensitivity has also been demonstrated in studies
examining ADNI cohort patients with respect to interac-
tions between APOE and changes in both neurocognitive
and neuroimaging end points [28]. In addition, in a study
that compared the effects of TOMM400523 and APOE ge-
notype on preclinical longitudinal memory decline, age
sensitivity was also observed. There was a significant
TOMM400523 effect before age 60 characterized by flat-
tened test-retest improvement for individuals carrying the
TOMM50-0523 VL/VL genotype, but no significant
APOE effect, and a significant APOE effect after age 60
[15]. It is notable that as age thresholds are increased,
the GBRA becomes less sensitive and more specific.
This is potentially a desirable quality for clinical trial
enrichment where specificity is particularly important
because screening is relatively low cost, but enrollment
of false-positives in a trial cohort is expensive. It is unclear
why sensitivity decreases with increasing the ageImaging (ADNI) MMSE**
SUVR* ADNI ADRC
1.90 6 0.06 26.45 6 0.13 26.10 6 0.29
1.52 6 0.07 27.37 6 0.16 28.37 1 0.24
CDR sum of boxes
** ADNI** ADRC**
0.04 1.95 6 0.09 2.41 6 0.22
0.03 1.33 6 0.11 0.73 6 0.20
spinal fluid; ADNI, Alzheimer’s Disease Neuroimaging Initiative; MMSE,
DR, clinical dementia rating; ADRC, Alzheimer’s Disease Research Center;
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changes of allele frequency in aging subjects as have
been noted for APOE alleles. Alternatively, it is possible
that the physiological effect of the genetic variation may
diminish as the biochemical environment changes in an
aging individual. It is possible that including other infor-
mation (family history, medical history, other genetic var-
iants, or further stratification of risk by age and genotype)
may increase sensitivity.
There are conflicting reports on whether the
TOMM400523 variant has an APOE-independent effect on
AD risk and AOO [6,12,16,29–31]. The primary study that
supports the use of both APOE and 0523 for LOAD risk
prediction is a single site (Duke; Bryan-ADRC), prospective
study with a clinical diagnosis [6,12,32].APOE-independent
effects of TOMM400523 are also reported in studies of
episodic memory [15,33,34] and brain imaging changes
associated with early AD expression [35]. The contradictory
studies involve meta-analysis of large cohorts that were
collected for Genome Wide Association Studies (GWAS);
these studies noted that there was no statistically significant
independent effect of TOMM400523 genotype above APOE
genotype on either AD risk or AD AOO [30,31]. There is
high linkage disequilibrium and in turn, statistical
correlation between the APOE and TOMM400523 variants
which limits assessment of independent effects by
statistical conditional analysis [36]. Therewere also substan-
tial differences in the studies considered for the genetic asso-
ciation analyses. Some of the component studies were
prospective, where incident cases were captured in the
course of the study. Other studies were cross-sectional, or
had a cross-sectional component, and would have contrib-
uted cases with retrospectively reported AOO data where
recall and survivor biases are likely to undermine the accu-
racy of the data. Roses et al. [16] provides a comprehensive
summary of factors to be considered for replication studies
of AOO of disease.
A limitation of the present study is the modest size and
length of time participants have been observed in the
ADNI and Bryan-ADRC cohorts, and, therefore, appro-
priate caution must be exercised when interpreting the
existent data. Although the performance characteristics
in the Bryan-ADRC and ADNI of the GBRA are encour-
aging, long-term longitudinal studies in additional larger,
diverse neurodegenerative disease cohorts are needed. As
additional testing data are accrued, refinement of the
GBRA will continue, potentially leading to improved
prognostic performance and broad applicability to both
clinical drug development and epidemiologic studies in
the future.
A decline in neurocognition is the hallmark of AD and
neurocognitive testing has routinely been demonstrated as
the most informative measure of future cognitive decline
[37]. Using the biomarker and neurocognitive testing data
from the ADNI cohort, Gomar et al. [38] found that cogni-
tive measures were the best predictors of conversion fromMCI to AD. It is encouraging that the GBRA performs
consistently with respect to the decline of neurocognitive
measures. This suggests that these biomarkers represent fea-
tures that are integral to or an important part of the cognitive
decline characteristic of AD.
Utilization of any biomarker is dependent not only on
its performance characteristics (NPV and PPV) but also
by the intended application, often referred to as “fit for
purpose.” In addition to the test performance, features
such as availability of specialized reagents, instruments
and/or qualified personnel, willingness of subjects to be
tested, invasiveness, cost/reimbursement, and consider-
ation of the clinical utility in the practice of medicine
contribute to the use of any given test. Any use of a
biomarker to enrich a clinical trial in normal subjects at
risk for conversion to disease symptoms needs to consider
how that test would be used in the practice of medicine in
a global environment. The GBRA relies on genomic DNA
using robust, widely available inexpensive testing of an
analyte that is unaffected by environmental, disease state,
or other conditions. A two-stage process is also possible,
where the GBRA would be used to initially screen sub-
jects for a prevention trial using an inexpensive blood
test followed by CSF and/or imaging biomarkers for
further screening of individuals likely to convert in the
time period of the trial. Although the GBRA was devel-
oped as a binary predictive algorithm for a delay-of-
disease-onset clinical trial of cognitively normal subjects
to high- and low-risk groups, the algorithm could also be
adapted to a continuous scale based on likelihood of con-
version within a prespecified time frame.
Combinations of biomarkers could conceivably be used
to further refine selection of subjects for clinical trials,
balancing cost and invasiveness of the assay with the
improvement in accuracy of conversion prediction in a
prespecified time frame. There is strong precedent for
the combination of APOE, CSF, imaging biomarkers,
and neurocognitive measures to improve predictive accu-
racy [39], and recent work using the BIOCARD cohort
[40,41] with 20 years of longitudinal follow-up has pro-
vided promising results [42]. Specifically, for prediction
of the onset of MCI in a 5-year time frame, the combina-
tion of six measures provided the best performance: Two
memory and thinking tests (the digit symbol and paired
associates immediate recall tests), levels of CSF, Ab,
and p-tau, and two MRI brain scans—one to assess the
thickness of the right entorhinal cortex and another to
measure the volume of the hippocampus. Accuracy of pre-
diction was reported as AUC 5 0.89, sensitivity 5 0.85,
and specificity 5 0.70 [42].
The data summarized previously suggest that age-
dependent risk of developing MCI due to AD can be strati-
fied informatively according to TOMM400523 and APOE
genotypes. This information has contributed to the design
of a pharmacogenetically enriched, double-blind, delay-of-
disease-onset clinical trial of cognitively normal subjects
M.W. Lutz et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 30-4442aged 65–83 years, inclusive, classified as having high or low
risk for development of cognitive symptoms over the course
of a 5-year study (TOMORROW trial; ClinicalTrials.gov
identifier 5 NCT01931566 [16]). In this study, high-risk
subjects are randomized to active therapy or placebo; low-
risk subjects are randomized to placebo only. Stratification
for risk of developing MCI due to AD during the study
before randomization is accomplished with the GBRA at
the beginning of the study (when neuropsychological testing
verifies normal cognition). The genetic GBRAwill be qual-
ified for use as a prognostic biomarker at the end of the phase
3 trial when the performance characteristics and ROC curves
can be calculated from the trial data which will provide a
large (n. 3000), prospectively sampled cohort. Once qual-
ified, the biomarker can be used as a companion
pharmacogenetics test for a therapeutic to delay the
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1. Systematic review: We used standard sources of
biomedical literature, recent reports from regulatory
agencies including the FDA and European Medical
Agency, information learned at scientific meetings,
and through contacts with colleagues to search, re-
view, and evaluate accumulated knowledge regarding
biomarkers for prediction of the risk of Alzheimer’s
disease (AD) in the context of research, clinical trials,
and clinical practice.
2. Interpretation: The genetic biomarker risk algo-
rithm (GBRA) described in this study is a prog-
nostic biomarker algorithm that demonstrates
equivalence to other AD biomarkers in wide-
spread use such as cerebrospinal fluid levels of
amyloid-beta 42 and phosphorylated tau and
structural imaging (functional magnetic resonance
imaging) of amyloid-beta burden. The GBRA is
also a good prognostic indicator of neurocognitive
scores; an indication of its utility for enrolling
subjects of high-risk for cognitive decline in
clinical outcome trials of AD therapies and its
relevance to fundamental changes associated with
AD. The results from this study support the
concept that age-dependent risk of developing
mild cognitive impairment (MCI) due to AD can
be stratified informatively according to translo-
case of outer mitochondrial membrane 40 homo-
log 0523 and apolipoprotein E genotypes.
3. Future directions: The GBRA described in this
study is a component of a pharmacogenetically en-
riched, double-blind, delay-of-disease onset (MCI
due to AD), TOMORROW trial; ClinicalTrials.gov
identifier 5 NCT01931566. Stratification for risk
of developing MCI due to AD during the study
before randomization is accomplished with the
GBRA. The GBRA will be qualified for use as a
prognostic biomarker at the end of the phase 3 trial
when the positive predictive value and negative
predictive value of the GBRA can be calculated
from the trial data which will provide a large
(n 5 5800), prospectively sampled cohort. Once
qualified, the biomarker can be used as a com-
panion PGx test for a therapeutic to delay the
onset of AD. Future studies will examine the
performance characteristics of the GBRA for non-
Caucasian ethnicities and will continue to evaluate
the utility of this biomarker in the context of
research and clinical applications for AD preven-
tion and treatment.
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